Prasugrel
- Generic Name
- Prasugrel
- Brand Names
- Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H20FNO3S
- CAS Number
- 150322-43-3
- Unique Ingredient Identifier
- 34K66TBT99
- Background
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
- Indication
用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。
- Associated Conditions
- Cardiovascular Events
Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study
- Conditions
- Acute Coronary SyndromeCardiovascular Diseases
- Interventions
- First Posted Date
- 2011-10-14
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 9
- Registration Number
- NCT01452152
- Locations
- 🇺🇸
Christiana Care Health System, Newark, Delaware, United States
🇺🇸University of Maryland School of Medicine, Baltimore, Maryland, United States
🇺🇸Sinai Center for Thrombosis Research, Baltimore, Maryland, United States
A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet
- Conditions
- Sickle Cell Disease
- Interventions
- First Posted Date
- 2011-09-07
- Last Posted Date
- 2012-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT01430091
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States
The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Medstar Health Research Institute
- Target Recruit Count
- 77
- Registration Number
- NCT01365221
- Locations
- 🇺🇸
The Heart Center, Huntsville, Alabama, United States
🇺🇸Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸Sinai Center for Thrombosis Research, Baltimore, Maryland, United States
Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention
- Conditions
- Coronary Artery DiseaseAcute Coronary Syndrome
- Interventions
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- University of Patras
- Target Recruit Count
- 44
- Registration Number
- NCT01360437
- Locations
- 🇬🇷
Cardiology Department Patras University Hospital, Rio, Patras, Greece
Pharmacokinetic Interaction Between Ritonavir and Prasugrel in Healthy Volunteers
- First Posted Date
- 2011-05-03
- Last Posted Date
- 2011-10-06
- Lead Sponsor
- University Hospital, Geneva
- Target Recruit Count
- 10
- Registration Number
- NCT01346800
- Locations
- 🇨🇭
University Hospitals, Geneva 14, Switzerland
Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI)
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2011-09-30
- Lead Sponsor
- University of Patras
- Target Recruit Count
- 35
- Registration Number
- NCT01338909
- Locations
- 🇬🇷
Patras University Hospital, Patras, Greece
Evaluating Additional Platelet Inhibition in Patients With High Platelet Reactivity Undergoing Percutaneous Coronary Intervention
- Conditions
- Cardiovascular DiseaseAcute Coronary Syndrome
- Interventions
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
- Target Recruit Count
- 44
- Registration Number
- NCT01339026
- Locations
- 🇩🇪
Universitätsklinikum Tübingen, Tübingen, Germany
Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOse
- Conditions
- ST Segment Elevation Myocardial Infarction
- Interventions
- First Posted Date
- 2011-04-15
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Università degli Studi di Ferrara
- Target Recruit Count
- 100
- Registration Number
- NCT01336348
- Locations
- 🇮🇹
Cardiology Unit, Ferrara, Italy
Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Stiftung Institut fuer Herzinfarktforschung
- Target Recruit Count
- 63
- Registration Number
- NCT01327534
- Locations
- 🇩🇪
Klinikum Ludwigshafen, Med. Klinik B, Ludwigshafen, Germany
🇩🇪Charité Campus Benjamin Franklin, Med. Klinik II, Berlin, Germany
🇫🇷Hospital Pitie-Salpetriere, Paris, France
The Effect of Prasugrel on Bronchial Hyperreactivity and on Markers of Inflammation in Patients With Chronic Asthma
- Conditions
- Chronic Asthma
- First Posted Date
- 2011-02-28
- Last Posted Date
- 2012-03-06
- Lead Sponsor
- University of Milan
- Target Recruit Count
- 26
- Registration Number
- NCT01305369
- Locations
- 🇮🇹
Medicina 3 Ospedale San Paolo Dipartimento di Medicina Chirurgia e Odontoiatria, Università di Milano, Milan, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.